The share price of biotech company Erasca fell by 3.5% in after-hours trading.

The company announced on the same day that it plans to raise up to $500 million through a public offering, with the securities being common shares. This fundraising proposal aims to provide financial support for the company's operations and pipeline development. Market concerns over equity dilution may be the main reason why the stock price dropped immediately after the news was released.